Cortexin at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Cortexin is a polypeptide complex extracted from the cerebral cortex of young pigs or cattle, standardized to contain a broad mixture of low-molecular-weight neuropeptides and free amino acids similar in concept to Cerebrolysin. It has been approved and in clinical use in Russia and several Eastern European countries for over 25 years for conditions including ischemic stroke, traumatic brain injury, encephalopathy, and age-related cognitive decline.
The active fractions of Cortexin exert neurotrophic effects (supporting neuronal survival), antioxidant effects (reducing ROS-mediated neuronal damage), and anti-excitotoxic effects (protecting against glutamate-induced neuronal death). Like Cerebrolysin, it contains peptide fractions that mimic the activity of BDNF, NGF, and other endogenous neurotrophins.
Russian clinical trials have demonstrated improvements in neurological deficits post-stroke, cognitive function in encephalopathy patients, and quality of life measures in cognitive decline. A 2014 meta-analysis of Russian RCTs found consistent positive effects on neurological outcomes. The limitations are the same as for other Russian neuropeptide complexes: most trials are small, conducted within Russia, and not published in high-impact Western journals.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.